Nuwellis logo

Nuwellis

NUWE | NASDAQ
Chart Builder DCF Calculator
$4.62
-$0.28 (-5.71%)
At close: Nov 16, 2026, 3:59 PM ET
$4.63
+$0.01 (+0.22%)
After-hours: Nov 16, 2026, 7:42 PM ET
-5.71%

Rating

Updated: Nov 16, 2026
47.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #335/1021 (Top 33%)

Key Statistics

Market Data

Market Cap $425.97K
1D Range
4.44 4.84
52W Range
2.90 1,319.85

Valuation (TTM)

PE 0
PB 0.04
EV/EBITDA N/A

Valuation (NTM)

Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Loading financial charts...

Profile

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow system...

Sector Healthcare
Employees 38
IPO Date Feb 16, 2012
Fiscal Year January - December

Latest News

Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

21 days ago · globenewswire.com

Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

1 month ago · globenewswire.com

Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System
Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

2 months ago · globenewswire.com

Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences
Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

2 months ago · globenewswire.com

Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity
Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

2 months ago · globenewswire.com

Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs
Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins

2 months ago · globenewswire.com

Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

3 months ago · globenewswire.com

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

3 months ago · seekingalpha.com

Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

Earnings

Latest Earnings
Nov 12, 2026
EPS
-$5.81
Beat +95.27%
REV
$2.21M
Miss -11.70%
Next Earnings
Mar 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.